1 NAME OF THE MEDICINE

Atenolol

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 50 mg of atenolol as the active ingredient.

Excipients with known effect:

Sulfites and sugars as lactose monohydrate.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Dosage form: uncoated tablet

The tablets are white, oblong, normal convex, marked AT/50 on one side, α on reverse.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Atenolol is indicated in the management of:

1. All grades of hypertension, including hypertension of renal origin
2. Frequent disabling angina without evidence of cardiac failure
3. Cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those associated with acute myocardial infarction)
4. Myocardial infarction – late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

4.2 DOSE AND METHOD OF ADMINISTRATION

Adults

Hypertension

Therapy should be initiated with 50 mg atenolol daily. This may be increased each week in daily doses of 50 mg up to a maximum of 200 mg. Where patients are controlled on daily doses of 50 to 100 mg, this may be given once daily. Doses above 100 mg daily should be given on a divided basis. Where necessary, a further reduction in blood pressure may be achieved by combining atenolol with other antihypertensive agents.

Patients can be transferred to atenolol from other antihypertensive treatments with the exception of clonidine (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Angina Pectoris

Therapy should be initiated with 50 mg of atenolol daily. This may be increased if required, to 100 mg daily given as a single or divided dose. It is unlikely that additional benefit will be gained by increasing the dose.

Cardiac Dysrhythmias

Having controlled the dysrhythmias with other intravenous agents, NOTEN given orally at a dosage of 50 to 100 mg daily will help maintain control.
Acute Myocardial Infarction – Late Intervention (> 12 hours from onset of chest pain)

Atenolol has been shown to reduce infarct size, reduce the incidence of ventricular dysrhythmias, reduce the need for opiate analgesics and reduce mortality in the first 7 post-infarction days, most of the benefit being in the first 48 hours. Data from other beta-blocker trials suggest that there is a significant reduction in mortality and a reduced incidence of non-fatal reinfarction if the beta blocker is continued for 1 to 3 years.

Maintenance oral therapy of 50 mg daily of NOTEN is recommended for 1 to 3 years following myocardial infarction, beginning after early intervention with other agents, or immediately in those patients who present more than 12 hours after suffering an acute myocardial infarction.

Impaired Renal Function

Since NOTEN is excreted via the kidneys, dosage should be adjusted in cases of severe impairment of renal function. No significant accumulation of NOTEN occurs at a creatinine clearance greater than 35 mL/min/1.73 m² (normal range is 100 to 150 mL/min/1.73 m²). For patients with a creatinine clearance of 15 to 35 mL/min/1.73 m² (equivalent to serum creatinine of 300 to 600 micromol/L) the dose should be 50 mg daily or 100 mg on alternate days. For patients with a creatinine clearance less than 15 mL/min/1.73 m² (equivalent to serum creatinine of greater than 600 micromol/L) the dose should be 50 mg on alternate days or 100 mg every fourth day.

Patients on haemodialysis should be given 50 mg orally after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur.

Children

There is no experience with atenolol in children.

Elderly

Dosage requirements may be reduced especially in patients with impaired renal function.

4.3 CONTRAINDICATIONS

1. Bronchospasm

Beta-adrenergic blockade of the smooth muscle of bronchi and bronchioles may result in an increased airways resistance. These drugs also reduce the effectiveness of asthma treatment. This may be dangerous in susceptible patients.

Therefore, beta-blockers are contraindicated in any patient with a history of airways obstruction or a tendency to bronchospasm. Use of cardioselective beta-blockers can also result in severe bronchospasm. If such therapy must be used, great caution should be exercised. Alternative therapy should be considered.

2. Congestive heart failure

3. Allergic disorders (including allergic rhinitis) which may suggest a predisposition to bronchospasm

4. Right ventricular failure secondary to pulmonary hypertension

5. Significant right ventricular hypertrophy

6. Sick sinus syndrome

7. Sinus bradycardia (less than 45 to 50 beats/minute)

8. Second- and third-degree A-V block

9. Shock (including cardiogenic and hypovolaemic shock)

10. Hypersensitivity to the drug
11. Anaesthesia with agents that produce myocardial depression (e.g. ether, chloroform, cyclopropane)
12. Metabolic acidosis
13. Hypotension
14. Severe peripheral arterial circulatory disturbances
15. Untreated phaeochromocytoma
16. Pregnancy and lactation (see Section 4.6 FERTILITY, PREGNANCY AND LACTATION)

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Cardiac Failure
Beta-blockade depresses myocardial contractility and may precipitate cardiac failure in some patients with a history of cardiac failure, chronic myocardial insufficiency or unsuspected cardiomyopathy as may occur in chronic alcoholism. In patients without a history of cardiac failure, continuing depression of the myocardium may lead to cardiac failure. If signs of cardiac failure present, the patients should be fully digitalised and/or given an ACE inhibitor or vasodilators with or without a diuretic and carefully monitored. If cardiac failure persists, atenolol should be withdrawn (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE – Abrupt Withdrawal of Therapy).

(Note: although congestive heart failure has been considered to be a contraindication to the use of beta-blockers, there is a growing literature on the experimental use of beta-adrenergic blocking drugs in heart failure. As further trials are needed to identify which patients are most likely to respond to which drugs, beta-blockers should not normally be prescribed for heart failure outside of specialist centres).

Abrupt Withdrawal of Therapy
Care should be taken if beta-blockers have to be discontinued abruptly in patients with coronary artery disease. Severe exacerbation of angina and precipitation of myocardial infarction and ventricular arrhythmias have occurred following abrupt discontinuation of beta-blockade in patients with ischaemic heart disease. Therefore, it is recommended that the dosage be reduced gradually over a period of about 8 to 14 days during which time the patient's progress should be reassessed. The drug may be reinstated temporarily if the angina worsens. If the drug must be withdrawn abruptly, close observation is required. In the peri-operative period, beta-blockers should not be withdrawn, unless indicated.

History of Anaphylactic Reaction
While taking beta-blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.

First Degree Heart Block
Due to its negative effect on conduction time, caution must be exercised if NOTEN is given to patients with first degree heart block.

Peripheral Circulation
Beta-blockade may impair the peripheral circulation and exacerbate the symptoms of peripheral vascular disease.

Prinzmetal Angina
There is a risk of exacerbating coronary artery spasm if patients with Prinzmetal or variant angina are treated with a beta-blocker.

If this treatment is essential, it should only be undertaken in a Coronary or Intensive Care Unit.
Bradycardia
If a treated patient develops symptoms which may be attributable to a slow heart rate, the dose may be reduced.

Use in Acute Myocardial Infarction
In addition to the contraindications listed (see Section 4.3 CONTRAINDICATIONS), patients with the following conditions are not suitable for treatment with NOTEN:

(a) Systolic blood pressure less than 120 mmHg (systolic blood pressure less than 120 mmHg in combination with a heart rate greater than 90 beats/min has a particularly poor prognosis).

(b) First degree A-V block. There is an increased incidence of cardiogenic shock (and need for inotropes), complete heart block and cardiovascular death in these patients, following atenolol.

Patients with atrial fibrillation following myocardial infarction, who were treated with atenolol, also had increased cardiovascular mortality compared with those not treated with atenolol. It is suggested that such patients be digitalised before NOTEN therapy is commenced.

Euthyroid Hyperthyroxinaemia
The effects of beta-blockers on thyroid hormone metabolism may result in elevations of serum free thyroxine (T4) levels. In the absence of any signs or symptoms of hyperthyroidism, additional investigation is necessary before a diagnosis of thyrotoxicosis can be made.

Anaesthesia and the Peri-Operative Period
Beta-blockade may have beneficial effects in decreasing the incidence of arrhythmias and myocardial ischaemia during anaesthesia and the post-operative period. It is currently recommended that maintenance of beta-blockade be continued peri-operatively. The anaesthetist must be made aware of beta-blockade because of the potential for interactions with other drugs, resulting in severe bradyarrhythmias and hypotension, the decreased reflex ability to compensate for blood loss, hypovolaemia and regional sympathetic blockade, and the increased propensity for vagal-induced bradycardia. Incidents of protracted severe hypotension or difficulty restoring normal cardiac rhythm during anaesthesia have been reported. Modern inhalational anaesthetic agents are generally well tolerated, although older agents (ether, cyclopropane, methoxyflurane, trichloroethylene) were sometimes associated with severe circulatory depression in the presence of beta-blockade.

Diabetes
Beta-blockers affect glucose metabolism and may mask some important premonitory signs of acute hypoglycaemia, such as tachycardia.

In patients with insulin or non-insulin dependent diabetes, especially labile diabetes, or with a history of spontaneous hypoglycaemia, beta-blockade may result in the loss of diabetic control and delayed recovery from hypoglycaemia. The dose of insulin or oral hypoglycaemic agent may need adjustment.

Other Metabolic Effects
Beta-adrenoreceptors are involved in the regulation of lipid as well as carbohydrate metabolism. Some drugs affect the lipid profile adversely, although the long-term clinical significance of this change is unknown and the effect appears to be less for drugs with intrinsic sympathomimetic activity.

Phaeochromocytoma
In patients with this condition, an alpha-blocking drug (e.g. phentolamine/phenoxybenzamine) should be administered before the beta-blocker to avoid exacerbation of hypertension.
Eye and Skin Reactions
Various skin rashes and conjunctival xerosis have been reported with beta-blockers. Cross-reactions may occur between beta-blockers, therefore substitutions within the group may not necessarily preclude occurrence of symptoms.

During the long-term treatment with the beta-blocking drug, practolol, a specific rash bearing a superficial resemblance to psoriasis was occasionally described. In a number of patients affected, this rash was accompanied by adverse effects on the eye (xerophthalmia and/or keratoconjunctivitis) of varying severity. This condition is called the oculomucocutaneous syndrome, or practolol syndrome. In a few patients, these eye changes occurred independently of a skin rash. On rare occasions, serous otitis media, sclerosing peritonitis, pericarditis and pleurisy have been reported. Although the practolol syndrome has not been observed in patients taking other beta-blockers, the possibility of such side effects occurring should be borne in mind.

More recently, an association between Peyronie's disease (a fibrosing induration of the penis) and various beta-blockers has been suggested but is not proven.

Allergic Conditions
These may be exaggerated by beta-blockade (e.g. allergic rhinitis during the pollen season and allergic reactions to bee and wasp stings). Beta-blockers should be avoided if there is a risk of bronchospasm.

Hyperthyroidism
Because beta-blockers may mask the clinical signs of developing or continuing hyperthyroidism, resulting in symptomatic improvement without any change in thyroid hormone status, special care should be exercised in those patients who are hyperthyroid and are also receiving beta-blockers.

Use in Hepatic Impairment
No data available.

Use in Renal Impairment
In patients with severe renal disease, haemodynamic changes following beta-blockade may impair renal function further. Beta-blockers which are excreted mainly by the kidney may require dose adjustment in patients with renal failure.

Use in the Elderly
See Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Paediatric Use
No data available.

Effects on Laboratory Tests
No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Concomitant Therapy with Calcium Antagonists
The concomitant use of beta-blockers and calcium antagonists with myocardial depressant and sinus node activity (e.g. verapamil and, to a lesser extent, diltiazem) may cause hypotension, bradycardia and asystole, particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities. Extreme caution is required if these drugs have to be used together.
The dihydropyridine calcium antagonists (e.g. nifedipine) have a weaker myocardial depressant effect and can be administered cautiously with beta-blockers. If excessive hypotension develops, the calcium antagonist should be stopped or the dosage reduced.

Antiarhythmic Drugs
Care should be taken when prescribing beta-blockers with antiarrhythmic drugs. Class I antiarrhythmic drugs (e.g. disopyramide) and the Class III agent amiodarone may have potentiating effect on atrial conduction time and induce negative inotropic effect, this is seen less frequently with quinidine; Class IB agents, tocainide, mexiletine and lidocaine (lignocaine); Class IC agents, flecainide and propafenone (not available in Australia); and the Class IV antiarrhythmic agents.

Use of Catecholamine-Depleting Agents
Concomitant use of drugs such as reserpine and guanethidine requires careful monitoring since the added effect of beta-blockade may produce an excessive reduction of the resting sympathetic nervous tone.

Clonidine
Concurrent use of beta-blockers and clonidine should be avoided because of the risk of adverse interaction and severe withdrawal symptoms. If administered concomitantly, the clonidine should not be discontinued until several days after the withdrawal of the beta-blocker.

Insulin and Oral Hypoglycaemics
See Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Diabetes.

Anaesthetics
Anaesthetics, such as methoxyflurane, are contraindicated with NOTEN (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE – Anaesthesia and the Peri-Operative Period).

Digitalis/Digitalis Glycosides
Digitalis/digitalis glycosides and beta-blockers are commonly used together, although there have been reports of excessive bradycardia when beta-blockers are used to treat digitalis intoxication.

Sympathomimetic Agents
Concomitant use of sympathomimetic agents, e.g. adrenaline (epinephrine), may counteract the effects of beta-blockers.

Prostaglandin Synthetase Inhibitors
Concomitant use of prostaglandin synthetase inhibiting drugs, e.g. ibuprofen and indometacin may decrease the hypotensive effects of beta-blockers.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility
No data available.

Use in Pregnancy
Pregnancy Category: C

Beta-adrenergic blocking agents may cause pharmacological effects such as bradycardia in the foetus and newborn infant. During the final part of pregnancy and parturition, these drugs should therefore only be given after weighing the needs of the mother against the risk to the foetus.
Atenolol crosses the placental barrier in pregnant women, and under steady-state conditions, maternal and foetal blood levels of atenolol are approximately equal.

No studies have been performed on the use of atenolol in the first trimester and the possibility of foetal injury cannot be excluded. Atenolol has been used under close supervision for the treatment of hypertension in the third trimester.

Administration of atenolol for longer periods to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation. The use of atenolol in women who are, or may become pregnant, requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters. In general, beta-blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion and early labour.

Atenolol has been shown to produce a dose-related increase in embryo/foetal resorptions in rats at doses equal to or greater than 50 mg/kg. Although similar effects were not seen in rabbits, the compound was not evaluated in rabbits at doses above 25 mg/kg.

**Use in Lactation**

There is significant accumulation of atenolol in breast milk. Caution should be exercised when atenolol is administered to nursing women and the infant should be regularly assessed for signs of beta-blockade.

4.7 **EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

Use is unlikely to result in any impairment of the ability of patients to drive or operate machinery. However, it should be taken into account, that occasionally dizziness or fatigue may occur.

4.8 **ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

Adverse effects reported in clinical trials of atenolol are mainly attributable to pharmacological actions. The adverse effects listed below have been observed in patients in clinical trials who have received dosages of about 100 mg per day. It is not possible to give percentage incidences for each reaction, but if all mild and transient reactions are included as well as more serious ones, up to 10% of patients may experience some form of adverse effects.

**More Common Adverse Effects**

*Gastrointestinal*

Gastrointestinal disturbances including indigestion, dry mouth, constipation.

*Nervous system*

Fatigue, dizziness.

*Respiratory*

Wheezing, bronchospasm (see Section 4.3 CONTRAINDICATIONS).

**Less Common Adverse Effects**

*Biochemical Abnormalities*

Increases in SGOT, blood urea and serum creatinine have been reported.

*Cardiovascular*

Bradycardia, left ventricular insufficiency, postural hypotenion which may be associated with syncope, intermittent claudication may occur if already present, Raynaud's phenomenon, cold extremities, deterioration in heart failure, heart block.
**Dermatological**
Rash, alopecia, psoriasiform skin rashes, exacerbation of psoriasis.

**Gastrointestinal**
Diarrhoea.

**Hepatic**
Elevations of transaminase levels have been seen infrequently, rare cases of hepatic toxicity including intrahepatic cholestasis have been reported.

**Genitourinary**
Impotence.

**Musculoskeletal**
Ataxia.

**Nervous System**
Vivid dreams, nightmares, paraesthesia, tinnitus, vertigo, malaise, headache, insomnia, mood changes, confusion.

**Ocular**
Dry eyes, visual disturbances.

**Psychiatric**
Hallucinations, depression, psychoses.

**Respiratory**
Asthma, dyspnoea, nasal congestion.

**Haemopoietic**
Thrombocytopenia, purpura. An increase in ANA (antinuclear antibodies) has been observed, however the clinical relevance of this is not clear.

**Serious or Life-Threatening Adverse Effects**
Myocardial insufficiency may require treatment with digitalis and diuretics. Bradycardia may respond to atropine. Bronchospasm may also be reversed with a beta2-stimulant. Hypotension, if severe, may require use of a vasopressor.

**Reporting Suspected Adverse Effects**

### 4.9 OVERDOSE
There have been no reports of overdosage to date with atenolol, but in overdosage with other beta-blockers, severe bradycardia and hypotension are commonly found. Acute heart failure and bronchospasm may also occur.

**Treatment**
**Severe Bradycardia**
Atropine, 1 to 2 mg intravenously, may be used to induce vagal blockade. If bradycardia persists an inotrope, such as intravenous isoprenaline (25 micrograms initially) may be given. In refractory cases, the use of a cardiac pacemaker may be considered.
**Hypotension**

Severe hypotension should respond to a sympathomimetic amine such as noradrenaline (norepinephrine). In refractory cases, the use of glucagon hydrochloride should be considered.

**Bronchospasm**

Therapy with a beta₂-stimulant such as salbutamol or terbutaline or therapy with aminophylline may be considered.

**Acute Cardiac Failure**

Conventional therapy with digitalis, diuretics and oxygen should be instituted immediately. In refractory cases, the use of intravenous isoprenaline, followed if necessary, by glucagon hydrochloride or intravenous aminophylline should be considered.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 PHARMACODYNAMIC PROPERTIES

**Mechanism of Action**

Atenolol is a beta-adrenoreceptor antagonist which acts preferentially on beta-receptors in the heart. Selectivity decreases with increasing dose. It has little intrinsic sympathomimetic activity and no membrane stabilising activity.

Atenolol is a racemic mixture and its activity resides in the S(-) enantiomer. It reduces raised blood pressure by an unknown mechanism, and also inhibits exercise-induced tachycardia and decreases plasma renin concentration. It causes slight airways obstruction but less than that seen with nonselective beta-blockers. The inhibition of exercise-induced tachycardia is correlated with blood levels but there is no correlation between plasma concentrations and antihypertensive effect. Atenolol is effective and well tolerated in most ethnic populations although the response may be less in Afro-Caribbean black patients.

The possible mechanism of the anti-anginal activity of atenolol appears to be due to a reduction in left ventricular work and oxygen utilisation resulting (mainly) from the decrease in heart rate and contractility.

The antiarrhythmic effect of atenolol is apparently due to its antisypathetic effect. There is no evidence that membrane stabilising activity or intrinsic sympathomimetic activity are necessary for antiarrhythmic efficacy. By its antisypathetic effect, atenolol depresses sinus node function, atrioventricular node function and prolongs atrial refractory periods. It has no direct effect on electrophysiological properties of the His-Purkinje system.

Because of their negative inotropic effects, beta-adrenoreceptor blocking agents should be avoided in uncontrolled heart failure.

**Clinical Trials**

No data available.

### 5.2 PHARMACOKINETIC PROPERTIES

**Absorption**

Although absorption of atenolol is variable and incomplete (40 to 60%) the virtual lack of hepatic metabolism results in relatively consistent systemic bioavailability compared to other beta-blockers. Peak blood levels occur 2 to 4 hours after administration of a single 100 mg oral dose and vary between 0.4 and 0.9 microgram/mL. Blood levels are consistent and the levels after chronic oral administration are in good agreement with those predicted from single dose results.
**Distribution**
Atenolol is distributed throughout the body tissues.

**Metabolism**
Less than 10% of a dose of atenolol is metabolised, the minor urinary metabolite identified being a hydroxylated derivative.

Plasma half-life, measured by blood level decay or urinary build up, varies from 7 to 9 hours.
In patients with impaired renal function, there is a progressive prolongation of the half-life.
In patients with normal renal function, the therapeutic effect, that is control of raised blood pressure, lasts for at least 24 hours following a 50 mg oral dose.

**Excretion**
The main route of elimination is renal excretion.

### 5.3 PRECLINICAL SAFETY DATA

**Genotoxicity**
No data available.

**Carcinogenicity**
No data available.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 LIST OF EXCIPIENTS
The tablets contain the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, purified talc, maize starch, crospovidone, sodium starch glycollate, povidone, magnesium stearate, vegetable hydrogenated oil and colloidal anhydrous silica.

#### 6.2 INCOMPATIBILITIES
Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

#### 6.3 SHELF LIFE
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

#### 6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store below 25°C. Protect from light and moisture.

#### 6.5 NATURE AND CONTENTS OF CONTAINER
Container type: PVC/PVDC/Aluminium blister packs or HDPE bottles or polypropylene pails (bulk dispensing use only)
Pack sizes: 7, 10 or 30 tablets (blister packs); 10 or 30 tablets (bottles); 11,940 or 59,700 tablets (pails).
Some strengths, pack sizes and/or pack types may not be marketed.
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES
Atenolol is structurally related to propranolol and differing from it by substitution on the aromatic ring. It is sparingly soluble in water, soluble in absolute ethanol, practically insoluble in ether.

Chemical Structure

![Chemical Structure Image]

Chemical name: 2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide
Molecular formula: C₁₄H₂₂N₂O₃
Molecular weight: 266.3 g/mol

7 MEDICINE SCHEDULE (POISONS STANDARD)
S4 (Prescription Only Medicine)

8 SPONSOR
Alphapharm Pty Ltd
Level 1, 30 The Bond
30 – 34 Hickson Road
Millers Point NSW 2000
www.mylan.com.au

9 DATE OF FIRST APPROVAL
5/10/1993

10 DATE OF REVISION
17/06/2021

Summary Table of Changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Update to S1 declaration to include sulfites</td>
</tr>
</tbody>
</table>

noten_p@Jun21/00